2026-01-17 - Analysis Report
# Novo Nordisk A/S ADR (NVO) Financial Report

## Company Overview
Novo Nordisk A/S ADR is a healthcare company.

## Return Rate Analysis
* Return rate of NVO = 53.30%
* Return rate of S&P 500 (VOO) = 93.36%
* Degree of divergence (simply the difference in cumulative return on the last day of the data) = -39.06% (Note: difference between the two rates)

## Alpha, Beta Analysis
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 0.0% | 19.0% | -4.0% | 0.8 | 102.4B |
| 2017-2019  | 37.0% | 13.6% | 20.0% | 0.6 | 128.6B |
| 2018-2020  | 1.0% | 12.5% | -20.0% | 0.6 | 155.2B |
| 2019-2021  | 58.0% | 13.0% | 15.0% | 0.6 | 248.8B |
| 2020-2022  | 58.0% | 23.2% | 60.0% | 0.6 | 300.7B |
| 2021-2023  | 87.0% | 23.2% | 86.0% | 0.5 | 459.7B |
| 2022-2024  | 18.0% | 40.5% | -1.0% | 0.5 | 382.2B |
| 2023-2025  | -52.0% | 59.7% | -114.0% | 0.7 | 226.1B |

## Stock Price Fluctuations
* Close = $62.33 
* Last-market = $57.12
* 5-day SMA = $59.57
* 20-day SMA = $54.41
* 60-day SMA = $50.73

## RSI, PPO Index Indicators
* Market Risk Indicator (MRI) = 0.80
* RSI = 76.91
* PPO = 1.05
* Recent (20 days) relative divergence change = 2.70 (+): improving
* 7-day Rank change = 0 (0): flat
* 7-day Dynamic Expected Return change = 0.00 (0): flat
* If {'price': 62.33, 'previousClose': 57.12, 'change': 9.12} is large, reflect the fluctuation issue (sharp rebound, sharp decline).

## Expected Return and Sharpe Ratio
* Expected Return (%) = 287.70%, Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.

## Recent News & Significant Events
* [2026-01-16] Novo Nordisk Stock (NVO) Jumps as UK Clears Higher Wegovy Dose - TipRanks
* [2026-01-16] Stocks making the biggest moves midday: Novo Nordisk, Vistra, GE Vernova, Regions Financial and more - CNBC
* [2026-01-13] Novo Nordisk: A Struggling Stock Vs. A Highly Profitable Strategy (NYSE:NVO) - Seeking Alpha
* [2026-01-16] Novo's Wegovy Pill Looks A Lot Like Zepbound — In One Week - Investor's Business Daily
* [2026-01-16] Novo Nordisk Stock Jumps. The Wegovy Pill Is Back in Focus - Yahoo Finance
* [2026-01-16] NVO Stock Is Rising Pre-Market – What Is The Wegovy News Driving Novo Nordisk Shares? - Stocktwits

## Analyst Opinions
* Analyst Consensus:
  - Key: Buy
  - Mean (1=StrongBuy~5=Sell): 2.38 (~Buy)
  - Opinions: 11
  - Target Price (avg/high/low): 55.79 / 73.15 / 41.49

## Comprehensive Analysis
The company has shown volatility in the Alpha, Beta Analysis table, with changing CAGR, MDD, Alpha, and Beta values across different periods. The stock price has shown fluctuations with a sharp rebound recently. The RSI, PPO index indicators, and Market Risk Indicator suggest a risk level of Medium and improving recent (20 days) relative divergence change. The Expected Return is high at 287.70%. Recent significant events include the UK clearing a higher Wegovy dose, which may impact the stock's performance.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.